The DOI matches its Crossref record; 70 of the 74 references it cites were found in a registry or an index; 14 of the 43 sources its claims cite were checked for support.
Modulation of K-Ras-Dependent Lung Tumorigenesis by MicroRNA-21
Open accessAbstract
Lung cancer is the leading cause of cancer-related deaths in the world, and non-small-cell lung cancer (NSCLC) accounts for 80% of cases. MicroRNA-21 (miR-21) expression is increased and predicts poor survival in NSCLC. Although miR-21 function has been studied in vitro with cancer cell lines, the role of miR-21 in tumor development in vivo is unknown. We utilize transgenic mice with loss-of-function and gain-of-function miR-21 alleles combined with a model of NSCLC to determine the role of miR-21 in lung cancer. We show that overexpression of miR-21 enhances tumorigenesis and that genetic deletion of miR-21 partially protects against tumor formation. MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
In a K-rasLA2 mouse model of NSCLC, miR-21 overexpression increased lung tumor number/area and proliferation, while miR-21 deletion reduced tumor burden and sensitized transformed MEFs to doxorubicin-induced apoptosis. miR-21 acts as a tumor promoter by repressing Ras/MEK/ERK negative regulators (Spry1, Spry2, Btg2, Pdcd4) and pro-apoptotic genes (Apaf1, Faslg, Pdcd4, RhoB).
Key findings
- CAG-miR-21;K-rasLA2 mice overexpressing miR-21 4–6 fold had significantly more gross lung tumors at 18 weeks and increased microscopic tumor number and total tumor area versus K-rasLA2 littermates; tumors showed increased proliferation, but survival did not differ, possibly due to decreased thymic tumor incidence.
- miR-21−/−;K-rasLA2 mice had significantly fewer surface lung tumors at 20 weeks and decreased total tumor area; no adenocarcinomas were noted in any of 14 miR-21−/−/K-rasLA2 animals evaluated, and miR-21 deletion did not alter Ki67 proliferation.
- miR-21 overexpression alone was not sufficient for tumorigenesis: CAG-miR-21 mice without K-rasLA2 (n = 39) followed up to 555 days showed no tumors.
- Reporter assays showed 13 of 24 putative mouse miR-21 target 3′UTRs were repressed by miR-21, with mutation of the miR-21 site abrogating repression in 11; in tumors, miR-21 overexpression decreased Spry1, Spry2, Btg2, Pdcd4, Apaf1, Faslg, and RhoB and increased ERK phosphorylation. K-ras activation increased miR-21 expression 4-fold; miR-21−/− MEFs formed fewer soft agar colonies and smaller xenograft tumors and showed increased doxorubicin-induced apoptosis.
Methods
- Generated conditional CAG-miR-21 overexpressing and miR-21−/− mice, crossed to the K-rasLA2 NSCLC model; comparisons were to littermate controls, with tumor burden assessed by H&E/ImageJ, proliferation by Ki67, and apoptosis by TUNEL.
- MEFs from wild-type and miR-21−/− mice were immortalized with SV40 large T/small t and transformed with H-rasG12V; assays included soft agar, xenografts, doxorubicin treatment (100 nM–10 μM for 12 h), and TUNEL (1 μM for 12 h).
- Luciferase reporter assays tested 24 putative miR-21 target 3′UTRs; Western blots were performed on micro-dissected tumors; statistics used two-tailed unpaired Student’s t-test with p < 0.05 considered significant.
Limitations
- No formal limitations section is present; the authors state miR-21 overexpression alone was not sufficient for tumorigenesis and that tumors arising after miR-21 deletion may have developed escape mechanisms, possibly explaining latency.
- The text notes miR-21 deletion did not alter apoptosis in lung lesions, suggesting those tumors escaped miR-21 regulatory effects; no adenocarcinomas were observed in 14 miR-21−/−;K-rasLA2 animals, a limited sample for that endpoint.
- Evident from the text: all mice used were of mixed genetic backgrounds, and findings are from a mouse K-rasLA2 model and transformed MEFs, so human NSCLC causality and therapeutic implications remain to be tested.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
14 of 43 cited sources checked · 6 supported · 0 flagged · accuracy not yet measured
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Four of the validated miR-21 target genes are known negative regulators of the Ras/MEK/ERK pathway: sprouty 1 (Spry1), sprouty 2 (Spry2), B-cell translocation gene 2 (Btg2), and programmed cell death 4 (Pdcd4).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
What the sources say
- Partly supportedcites Casci et al., 1999 sourceExperimental — accuracy not yet measured
The Discussion identifies Drosophila Sprouty as an inhibitor of Ras/MAP kinase signaling. The paper predicts that mammalian Sprouty homologs may have the same function, but does not establish it for Spry1 or Spry2 specifically. It does not address Btg2, Pdcd4, or whether these genes are validated miR-21 targets. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites Hanafusa et al., 2002 source
- Not matchedcites Lo et al., 2006
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Oncogenic Ras activation has been shown to increase the expression of Spry2, providing feedback inhibition of Ras activation (Shaw et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Shaw et al., 2007 sourceExperimental — accuracy not yet measured
In “Negative feedback signaling in development” (page not available), the paper reports that oncogenic K-ras up-regulates Spry-2 and that Spry-2 inhibits MAPK activation. It does not establish that Spry-2 inhibits activation of Ras itself; it describes possible effects at different points in the Ras/MAPK pathway, including downstream of activated K-ras. (LLM, conf=0.86)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that over-expression of miR-21 enhances tumorigenesis and genetic deletion of miR-21 partially protects against tumor formation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“K-ras activation in the tumors of K-rasLA2 mice increased miR-21 expression 4-fold similar to the expression level in the CAG-miR-21 transgenic mouse lung.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly decreased with miR-21 deletion (Figure 2D).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression in CAG-miR-21;K-rasLA2 mutant tumors decreases Spry1, Spry2, and Btg2 protein expression compared to K-rasLA2 tumors (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This is may be explained by a decreased incidence of thymic tumors in CAG-miR-21;K-rasLA2 mutant mice compared to K-rasLA2 controls (Figure 1I), thus contributing to the enhanced survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There was no difference in proliferation between the miR-21−/− and wild type MEFs (Figure S2C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Total tumor area as a proportion of total lung area was significantly increased with miR-21 over-expression (Figure 1E).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- Probably not a substantial claim. 25
- It may state two separate claims as one. 35
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Recently, miR-21 expression levels have proven useful prognostic markers in non-small cell lung cancer (Markou et al., 2008; Yanaihara et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Markou et al., 2008 source
The discussion reports that mature miR-21 overexpression in NSCLC was associated with lung-cancer death and was an independent prognostic factor in multivariate analysis. The authors caution that the small number of events requires further confirmation, so the finding should not be read as a validated clinical test. (LLM, conf=0.88)
- Partly supportedcites Yanaihara et al., 2006 sourceExperimental — accuracy not yet measured
The Results report that high hsa-mir-21 expression was associated with significantly worse survival in lung adenocarcinoma patients. They do not establish miR-21 as a validated prognostic marker across non-small cell lung cancer: the reported prognostic validation focused on other miRNAs. (LLM, conf=0.88)
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The level of miR-21 expression in sputum distinguishes NSCLC patients from cancer-free controls with a greater sensitivity than conventional cytology (Xie et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Supportedcites Xie et al., 2009 source
The Results section, under “Comparison of cytology and measurement of altered miRNA expression in sputum,” reports 69.66% sensitivity for sputum miR-21 measurement versus 47.82% for conventional sputum cytology. The study examined sputum from 23 NSCLC patients and 17 cancer-free subjects, matching the claimed comparison. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Several components of the PI3K pathway, including PTEN and PIK3R1, have been suggested as miR-21 target genes (Meng et al., 2007); however, miR-21 over-expression did not alter PTEN and PIK3R1 protein expression or Akt phosphorylation (Figure S3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
What the sources say
- Partly supportedcites Meng et al., 2007 sourceExperimental — accuracy not yet measured
The Results identify PTEN as a miR-21 target, and the Discussion places PTEN in the PI3K pathway. The passages do not identify PIK3R1 as a miR-21 target. The statement that over-expression did not alter protein expression or Akt phosphorylation is attributed to the citing paper’s Figure S3B, not to Meng et al. (LLM, conf=0.87)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the Cdc25a target gene (Wang et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Partly supportedcites Wang et al., 2009 sourceExperimental — accuracy not yet measured
The Results report targeted miR-21 deletion in RKO and DLD1 cells, and the Discussion links miR-21, Cdc25A, cell-cycle progression, and checkpoint activation. However, the Discussion describes a contribution to tumorigenesis as a possibility, not a demonstrated outcome; the claim's “revealed” overstates that conclusion. (LLM, conf=0.88)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“As well, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Supportedcites Huang et al., 2009 source
The paired citations and “respectively” attribute the HER2/neu finding in breast carcinoma cells to Huang et al. In “Ectopic Expression of HER2/neu Induces miR-21 Upregulation” (Fig. 1A; page not provided), the paper reports that HER2/neu expression increased miR-21 in a human breast cancer cell line. The EGFR finding in lung cells is not attributed to this source. (LLM, conf=0.94)
- Not checked — no full text of the sourcecites Seike et al., 2009 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Zhang et al. showed in a human gastric cancer cell line that forced over-expression of miR-21 enhanced tumor proliferation and invasion”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
In the Results sections on proliferation and invasion (page numbers not provided), the paper reports that transfecting AGS human gastric cancer cells with a miR-21 expression construct significantly increased proliferation and strengthened invasion. This matches the claim about forced over-expression in a human gastric cancer cell line. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004; Minowada and Miller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Minowada and Miller, 2004 source
- Partly supportedcites Minowada and Miller, 2009 sourceExperimental — accuracy not yet measured
The study summary and Discussion (page unavailable) report fewer and smaller urethane-induced lung tumors in mice overexpressing Sprouty 2, supporting a tumor-suppressive effect in that mouse model. The Discussion says the findings are consistent with antagonism of Ras signaling, but the mechanism remains unclear; this paper does not demonstrate inhibition of MEK/ERK signaling. The citing sentence attributes the human NSCLC portion to a separate citation, not to this paper. (LLM, conf=0.83)
- Supportedcites Shaw et al., 2007 source
The Negative feedback signaling in development section reports that Spry-2 inhibits MAPK activation in K-ras G12D mouse lungs. The tumor-suppression section concludes that Spry-2 limits K-ras-driven mouse lung tumor development; a correction in Additional information says its revised results do not change that conclusion. The citing sentence attributes the human finding to Sutterluty et al., not to this paper. (LLM, conf=0.90)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma according to the Mouse Models of Human Cancer Consortium recommendations.(Nikitin et al., 2004)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Tumor Grading
What the sources say
- Partly supportedcites Nikitin et al., 2004 sourceExperimental — accuracy not yet measured
The Development of Recommendations section says the consortium prepared and reviewed H&E-stained sections, and the classification defines hyperplasia, atypical adenomatous hyperplasia, adenoma, and adenocarcinoma. The cited paper does not identify “adenoma with typia” as a recommended category. The survival-cohort analysis describes the citing authors’ own work, not an analysis reported by Nikitin et al. (LLM, conf=0.85)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“knock-down of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis (Zhang et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Supportedcites Zhang et al., 2008 source
The Abstract states that inhibiting miR-21 in AGS human gastric cancer cells significantly reduced proliferation and increased apoptosis. The ‘miR-21 Increases Cell Proliferation and Inhibits Cell Apoptosis’ section reports both effects after transfection with an anti-miR-21 inhibitor. (LLM, conf=0.95)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Partly supportedcites Hutvagner et al., 2004 sourceExperimental — accuracy not yet measured
The Results and Discussion report that 2′-O-methyl oligonucleotides inhibit specific miRNAs and can be used to study their function in C. elegans. The paper presents them as a research tool; it does not establish that they facilitate new cancer therapeutic strategies. (LLM, conf=0.87)
- Not checked — no full text of the sourcecites Krutzfeldt et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK, Cdc25a, Map2k3, NfiB, Trp63 and Ski have been shown to be miR-21 target genes in vitro, but only RECK showed decreased protein levels in the CAG-miR-21;K-rasLA2 tumors (Figure S3A).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR21−/−;K-rasLA2 mice all develop lung tumors, but show an increased incidence of thymic lymphoma (Figure 2F).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Caspase 3 and K-ras do not contain miR-21 sites in their 3′ UTR and the 3′ UTR luciferase reporter activity is not suppressed by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The decrease in Spry1, Spry2, and Btg2 in CAG-miR-21;K-rasLA2 tumors correlates with increased Ras pathway activity, shown by increased ERK phosphorylation (Figure 4C).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show miR-21 dependent repression of the mouse Apaf1 3′ UTR reporter; however, the miR-21 site in the human APAF1 3′ UTR is conserved in primates but not conserved in the mouse.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple tumor suppressor genes
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Figure S1E)(van Rooij et al., 2006; van Rooij et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Apaf1, Pdcd4, Faslg, and RhoB were validated as direct miR-21 target genes by luciferase reporter assays; however, caspase 3 was not directly regulated by miR-21 (Figure 3B).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 over-expression increased the incidence of all tumor grades without increasing the rate of conversion to adenocarcinoma, suggesting that miR-21 participates in tumor promotion rather than progression and metastasis in this model (Figure 1J and 1K).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Unlike K-rasLA1;p53−/− compound mutant mice (Johnson et al., 2001), we did not observe an increased tumor spectrum or increased metastasis in the CAG-miR-21;K-rasLA2 mutant mice.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Although miR-21 function has been studied in vitro using cancer cell lines, the role of miR-21 in tumor development in vivo is unknown.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“MiR-21 drives tumorigenesis through inhibition of negative regulators of the Ras/MEK/ERK pathway and inhibition of apoptosis.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > Abstract
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“A large scale survey to determine the miRNA signature of 540 tumor samples including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue revealed miR-21 was the only miRNA up-regulated in all these tumors (Volinia et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Volinia et al., 2006 source
Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Further miRNA profiling in tumor samples and cancer cell lines show increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B-cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“CAG-miR-21 transgenic mice were viable, fertile and born in expected Mendelian ratios.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metastasis (Zhu et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Zhu et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 deletion suppresses Ras-driven transformation In vitro
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Rests on an assumption: The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data illustrate that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are involved in apoptosis thus promoting survival.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 suppresses apoptosis by targeting proapoptotic genes
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
In the paper
“Knockdown of miR-21 in cultured glioblastoma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an anti-apoptotic factor (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“K-rasLA2 mice develop multi-focal lung tumors with 100% penetrance, and less frequently develop thymic lymphomas and skin papillomas (Johnson et al., 2001).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
What the sources say
- Not checked — no full text of the sourcecites Johnson et al., 2001 source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data suggest that miR-21 over-expression in human tumors does not simply reflect cancer pathology, but instead enhances aspects of the pathology of NSCLC.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 over-expression promotes tumor development In vivo
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Previously, an autoregulatory loop connecting miR-21 and Ras activation through AP-1 was illustrated in a rat thyroid cell system (Talotta et al., 2009).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > Oncogenic Ras activation increases miR-21 expression In vivo
What the sources say
- Not checked — no full text of the sourcecites Talotta et al., 2009 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These data show that miR-21 over-expression decreases the protein expression of four miR-21 target genes that are tumor suppressors and negative regulators of the Ras/MEK/ERK pathway resulting in a concomitant increased ERK activity.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > RESULTS > miR-21 targets multiple negative regulators of Ras signaling
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
- Rests on an assumption: The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
In the paper
“In breast cancer MCF-7 cells, miR-21 knock-down results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > INTRODUCTION
What the sources say
- Not matchedcites Si et al., 2007
Couldn’t be matched to a paper in Crossref, so it can’t be checked.
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Not matched
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All mice used in these studies were of mixed genetic backgrounds and all comparisons were performed on littermate controls.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > EXPERIMENTAL PROCEDURES > Mouse Strains
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
None of the sources cited for this claim have been checked yet.
In the paper
“PDCD4 is a pro-apoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2007; Bitomsky et al., 2008; Frankel et al., 2007; Lu et al., 2008; Zhang et al., 2006).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP bound, active state (Buganim et al., 2010).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Knock-down of miR-21 in glioblastoma cell lines triggers the activation of caspases and increases apoptosis (Chan et al., 2005).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chan et al., 2005 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009)”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Kim et al., 2009 source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Although the reductions in protein levels of individual miR-21 targets appear modest with miR-21 over-expression, collectively this diminution of tumor suppressor activity allows for more robust tumor formation through relieving multiple nodes of inhibition of the Ras/MEK/ERK pathway, thus facilitating tumor proliferation.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The antibodies used in Western blots specifically detect the intended target proteins.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“We show that Ras activation increases miR-21 expression and in turn decreasing the expression of Spry2.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“miR-21 modulates several components critical to NSCLC pathogenesis through both relieving antagonism of the Ras pathway and reducing apoptotic effectors (Figure 7).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
In the paper
“RhoB expression is down-regulated in human NSCLC suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sato et al., 2007 source
Strength:hedged· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Relieving miR-21 inhibition of pro-apoptotic genes could provide a means to augment the effect of current chemotherapy.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Rests on an assumption: Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
In the paper
“MiR-21 targets SPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Sayed et al., 2008 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our results show that miR-21 expression modulates tumor number, incidence and size in a mouse lung cancer model initiated by oncogenic K-rasG12D, consistent with miR-21 functioning as a tumor promoter.”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
- Rests on an assumption: The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
In the paper
“Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Hwang et al., 2007 source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
In the paper
“Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003).”
§ Modulation of K-ras-dependent lung tumorigenesis by microRNA-21 > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites Chen et al., 2003 source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
The K-rasLA2 mouse model is a valid model of human NSCLC for studying miR-21.
“To explore the role of miR-21 in the pathogenesis of NSCLC, we utilized the K-rasLA2 murine lung cancer model, which harbors a targeted, latent K-ras G12D allele that is activated by two distinct recombination events (Johnson et al., 2001).”
The paper relies on this without support.
The level of miR-21 over-expression achieved in CAG-miR-21 mice (4–6 fold) is representative of the increased miR-21 expression in human NSCLC.
“which globally over-expressed miR-21 4–6 fold over normal levels of expression (Figure S1B–D).”
The paper relies on this without support.
The miR-21 knockout mice do not have compensatory molecular changes that confound the interpretation of tumorigenesis experiments.
“Homozygous miR-21 knock-out mice are viable, fertile, and born in expected Mendelian ratios without any gross phenotypic differences compared to wild type or heterozygous littermates, and without a cardiac phenotype (D.P., E.V.R. and E.N.O., manuscript in preparation).”
The paper relies on this without support.
The antibodies used in Western blots specifically detect the intended target proteins.
“We isolated individual tumors from mice, made whole tumor lysates, and performed Western blots for putative miR-21 targets to address the effect of miR-21 expression on the protein levels of the miR-21 target genes in vivo within lung tumors.”
The paper relies on this without support.
The luciferase reporter assays in COS cells reflect endogenous miR-21 target regulation in mouse lung tumors.
“Reporter assays in COS cells revealed miR-21 dependent repression of 13 of the 24 3′UTRs”
The paper relies on this without support.
MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.
“MicroRNAs are small non-coding RNAs that are commonly dysregulated in human malignancies and play a substantial role in the pathogenesis and survival of many cancers.”
The paper relies on this without support.
MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).
“MiR-21 is over-expressed in the majority of human malignancies including non-small cell lung cancer (NSCLC).”
The paper relies on this without support.
It is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.
“However, it is not clear whether miR-21 determines important aspects of lung cancer pathogenesis or is instead simply a marker for advanced disease.”
The paper relies on this without support.
Spry1, Spry2, Btg2, and Pdcd4 act as negative regulators of the Ras/MEK/ERK pathway.
“which act as negative regulators of the Ras/MEK/ERK pathway”
The paper relies on this without support.
Apaf1, Faslg, Pdcd4 and RhoB promote apoptosis.
“which promote apoptosis”
Citations
Cites
Bartel (2004) · doi:10.1016/s0092-8674(04)00045-5 · Cited by 34,714
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855 · cited 2×
“Expression of approximately 30% of human proteins appears to be regulated by miRNAs (Lewis et al., 2005).”
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1997 · Cited by 7,668 · cited 2×
“…including non-small-cell lung cancer (NSCLC) (Volinia et al., 2006), and are predictive of tumor classification, prognosis, and response to therapy (Calin and Croce, 2006). miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than…”
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884 · cited 4×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
InfluentialA microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697 · cited 4×
“A large-scale survey to determine the miRNA signature of 540 tumor samples—including lung, breast, stomach, prostate, colon, and pancreatic tumors and their respective normal adjacent tissue—revealed miR-21 was the only miRNA upregulated in all these tumors (Volinia et al., 2006).”
InfluentialCombinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603 · cited 2×
“, 2007), and PicTar (Krek et al., 2005).”
Silencing of microRNAs in vivo with ‘antagomirs’
Krützfeldt, J., Rajewsky, N., Braich, R., Rajeev, K. G., Tuschl, T., Manoharan, M., & Stoffel, M. (2005) · Nature · doi:10.1038/nature04303 · Cited by 3,949 · cited 2×
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
MicroRNA Targeting Specificity in Mammals: Determinants beyond Seed Pairing
Grimson, A., Farh, K. K.-H., Johnston, W. K., Garrett-Engele, P., Lim, L. P., & Bartel, D. P. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.06.017 · Cited by 3,766 · cited 2×
“Can miR-21 Targets Multiple Tumor Suppressor Genes To identify miR-21 effectors responsible for phenotypes observed, we utilized two algorithms that predict the mRNA targets of miRNAs, TargetScan (Grimson et al., 2007), and PicTar (Krek et al.”
The impact of microRNAs on protein output
Baek, D., Villén, J., Shin, C., Camargo, F. D., Gygi, S. P., & Bartel, D. P. (2008) · Nature · doi:10.1038/nature07242 · Cited by 3,592 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Widespread changes in protein synthesis induced by microRNAs
Selbach, M., Schwanhäusser, B., Thierfelder, N., Fang, Z., Khanin, R., & Rajewsky, N. (2008) · Nature · doi:10.1038/nature07228 · Cited by 3,429 · cited 2×
“Through interactions with 30 UTRs, miRNAs can modulate the expression of many genes simultaneously, often regulating individual signaling pathways at multiple levels (Baek et al., 2008; Selbach et al., 2008).”
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023 · cited 1×
“Recently, miR-21 expression levels have proven useful prognostic markers in NSCLC (Markou et al., 2008; Yanai- hara et al., 2006).”
MicroRNA-21 Regulates Expression of the PTEN Tumor Suppressor Gene in Human Hepatocellular Cancer
Meng, F., Henson, R., Wehbe–Janek, H., Ghoshal, K., Jacob, S. T., & Patel, T. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.022 · Cited by 2,773 · cited 4×
“, 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al.”
InfluentialMicroRNA-21 Is an Antiapoptotic Factor in Human Glioblastoma Cells
Chan, J. A., Krichevsky, A. M., & Kosik, K. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0137 · Cited by 2,557 · cited 5×
“Knockdown of miR-21 in cultured glioblas- toma cells activates caspases leading to apoptotic cell death, suggesting miR-21 is an antiapoptotic factor (Chan et al., 2005).”
InfluentialCancer burden in the year 2000. The global picture
Parkin, D. M., Bray, F. I., & Devesa, S. S. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00267-2 · Cited by 2,169 · cited 2×
“2 million new cases each year (Parkin et al., 2001).”
InfluentialAsangani, I. A., Rasheed, S. A. K., Nikolova, D. A., Leupold, J. H., Colburn, N. H., Post, S., & Allgayer, H. (2008) · Oncogene · doi:10.1038/sj.onc.1210856 · Cited by 1,882 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis
van Rooij, E., Sutherland, L. B., Thatcher, J. E., DiMaio, J. M., Naseem, R. H., Marshall, W. S., Hill, J. A., & Olson, E. N. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805038105 · Cited by 1,870 · cited 2×
“…in expected Mendelian ratios. miR-21 expression increases in mouse models of cardiac hypertrophy and following myocardial infarction; however, adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Fig- ure S1E) (van Rooij et al., 2006; van Rooij et al., 2008).”
Self-citationSi, M.-L., Zhu, S., Wu, H., Lu, Z., Wu, F., & Mo, Y.-Y. (2007) · Oncogene · doi:10.1038/sj.onc.1210083 · Cited by 1,600 · cited 2×
“In breast cancer MCF-7 cells, miR-21 knockdown results in suppression of cell growth in vitro and tumor growth in xenografts (Si et al., 2007).”
van Rooij, E., Sutherland, L. B., Liu, N., Williams, A. H., McAnally, J., Gerard, R. D., Richardson, J. A., & Olson, E. N. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608791103 · Cited by 1,498 · cited 1×
“…in expected Mendelian ratios. miR-21 expression increases in mouse models of cardiac hypertrophy and following myocardial infarction; however, adult male CAG-miR-21 mice showed no signs of heart failure compared to littermate controls (Fig- ure S1E) (van Rooij et al., 2006; van Rooij et al., 2008).”
Self-citationTherapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452 · cited 2×
“Recently, gain- and loss-of-function studies in mice demonstrate critical roles for miR-26a and miR-9 in hepatocellular carcinoma and breast cancer metastasis, respectively (Kota et al., 2009; Ma et al., 2010).”
MicroRNA Signatures in Human Ovarian Cancer
Iorio, M. V., Visone, R., Leva, G. D., Donati, V. L., Petrocca, F., Casalini, P., Taccioli, C., Volinia, S., Liu, C.-G., Alder, H., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1936 · Cited by 1,396 · cited 2×
“…lines showed increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis
Ma, L., Young, J. J., Prabhala, H. K., Pan, E., Mestdagh, P., Muth, D., Teruya‐Feldstein, J., Reinhardt, F., Önder, T. T., Valastyan, S., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2024 · Cited by 1,358 · cited 2×
“Recently, gain- and loss-of-function studies in mice demonstrate critical roles for miR-26a and miR-9 in hepatocellular carcinoma and breast cancer metastasis, respectively (Kota et al., 2009; Ma et al., 2010).”
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice
Johnson, L., Mercer, K., Greenbaum, D., Bronson, R. T., Crowley, D., Tuveson, D. A., & Jacks, T. (2001) · Nature · doi:10.1038/35074129 · Cited by 1,179 · cited 7×
“Unlike K-ras;p53 / compound mutant mice (Johnson et al., 2001), we did not observe an increased tumor spectrum or increased metastasis in the CAGmiR-21;K-rasmutant mice.”
InfluentialFrankel, L. B., Christoffersen, N. R., Jacobsen, A., Lindow, M., Krogh, A., & Lund, A. H. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m707224200 · Cited by 1,141 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
Extensive modulation of a set of microRNAs in primary glioblastoma
Ciafrè, S. A., Galardi, S., Mangiola, A., Ferracin, M., Liu, C.-G., Sabatino, G., Negrini, M., Maira, G., Croce, C. M., & Farace, M. G. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.07.030 · Cited by 1,096 · cited 2×
“Further miRNA profiling in tumor samples and cancer cell lines showed increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al.”
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Zhu, S., Wu, H., Wu, F., Nie, D., Sheng, S., & Mo, Y.-Y. (2008) · Cell Research · doi:10.1038/cr.2008.24 · Cited by 1,051 · cited 2×
“Knockdown of miR-21 in the metastatic breast cancer MD-MBA-231 cells reduced invasion and metas- tasis (Zhu et al., 2008).”
MicroRNAs and Cancer: Short RNAs Go a Long Way
Ventura, A., & Jacks, T. (2009) · Cell · doi:10.1016/j.cell.2009.02.005 · Cited by 898 · cited 2×
“MiR-21 , suggesting that miR-21 inhibition could be of therapeutic c. in human cancer pathogenesis (Ventura and Jacks, 2009).”
MicroRNA-21 targets tumor suppressor genes in invasion and metastasis
Shuomin, Zhu, Hailong, H., Wu, Fangting, Daotai, Nie, Shijie, Sheng, Yin-Yuan, et al. (2008) · Cell Research · Cited by 831
OncomiRs: the discovery and progress of microRNAs in cancers
Cho, W. C. S. (2007) · Molecular Cancer · doi:10.1186/1476-4598-6-60 · Cited by 717 · cited 2×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
MicroRNA-21 promotes cell transformation by targeting the programmed cell death 4 gene
Lu, Z., Liu, M., Stribinskis, V, Klinge, C. M., Ramos, K. S., Colburn, N. H., & Li, Y. (2008) · Oncogene · doi:10.1038/onc.2008.72 · Cited by 711 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
Sequence-specific inhibition of small RNA function
Hutvágner, G., Simard, M. J., Mello, C. C., & Zamore, P. D. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020098 · Cited by 584 · cited 2×
“Methods have been developed to manipulate miRNA function pharmacologically, facilitating the development of new cancer therapeutic strategies (Hutvagner et al., 2004; Krutzfeldt et al., 2005).”
Sprouty1 and Sprouty2 provide a control mechanism for the Ras/MAPK signalling pathway
Hanafusa, H., Torii, S., Yasunaga, T., & Nishida, E. (2002) · Nature Cell Biology · doi:10.1038/ncb867 · Cited by 566 · cited 13×
“We hypothesize that increased miR-21 expression potentiates Ras signaling through inhibition of antagonists of the Ras pathway, such as Spry1, Spry2, Btg2, and Pdcd4 (Casci et al., 1999; Hanafusa et al., 2002; Lo et al., 2006).”
InfluentialMiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers
Seike, M., Goto, A., Okano, T., Bowman, E. D., Schetter, A. J., Horikawa, I., Mathe, E. A., Jen, J., Yang, P., Sugimura, H., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0905234106 · Cited by 500 · cited 2×
“In addition, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
Yang, H.-S., Jansen, A. P., Komar, A. A., Zheng, X., Merrick, W. C., Costes, S., Lockett, S. J., Sonenberg, N., & Colburn, N. H. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.1.26-37.2003 · Cited by 494 · cited 2×
“, 2009), a known negative regulator of AP-1 transactivation (Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang et al., 2001).”
miR-21 plays a pivotal role in gastric cancer pathogenesis and progression
Zhang, Z., Li, Z., Gao, C., Chen, P., Chen, J., Liu, W., Xiao, S., & Lu, H. (2008) · Laboratory Investigation · doi:10.1038/labinvest.2008.94 · Cited by 477 · cited 1×
“Zhang et al. (2008) showed in a human gastric cancer cell line that forced overexpression of miR-21 enhanced tumor proliferation and invasion and knock- down of miR-21 resulted in a marked reduction in proliferation and increase in apoptosis.”
Sprouty, an intracellular inhibitor of Ras signaling
Casci, T., Vinós, J., & Freeman, M. (1999) · Cell · doi:10.1016/s0092-8674(00)80576-0 · Cited by 467 · cited 4×
“We hypothesize that increased miR-21 expression potentiates Ras signaling through inhibition of antagonists of the Ras pathway, such as Spry1, Spry2, Btg2, and Pdcd4 (Casci et al., 1999; Hanafusa et al., 2002; Lo et al., 2006).”
InfluentialmiR-21 as a key regulator of oncogenic processes
Selçuklu, S. D., Donoghue, M. T. A., & Spillane, C. (2009) · Biochemical Society Transactions · doi:10.1042/bst0370918 · Cited by 460 · cited 2×
“Many of the miR-21-predicted targets have been reported to function as tumor suppressors and have been validated in vitro in previous studies (Selcuklu et al., 2009).”
Markou, A., Tsaroucha, E. G., Kaklamanis, L., Fotinou, M., Georgoulias, V., & Lianidou, E. S. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2007.101741 · Cited by 441 · cited 2×
“Recently, miR-21 expression levels have proven useful prognostic markers in NSCLC (Markou et al., 2008; Yanaihara et al., 2006).”
Patterns of Known and Novel Small RNAs in Human Cervical Cancer
Lui, W., Pourmand, N., Patterson, B. K., & Fire, A. Z. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-0561 · Cited by 432 · cited 1×
“…lines showed increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and cervical carcinoma (Lui et al., 2007).”
Lawrie, C. H., Soneji, S., Marafioti, T., Cooper, C. D. O., Palazzo, S., Paterson, J. C., Cattan, H., Enver, T., Mager, R., Boultwood, J., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22800 · Cited by 415 · cited 2×
“, 2007), B cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al.”
MicroRNAs modulate the chemosensitivity of tumor cells
Blower, P. E., Chung, J.-H., Verducci, J. S., Lin, S., Park, J. K., Dai, Z., Liu, C., Schmittgen, T. D., Reinhold, W. C., Croce, C. M., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0573 · Cited by 359 · cited 2×
“miR-21 Deletion Sensitizes Cells to DNA-Damaging Chemotherapy Recent studies illustrate that miRNAs modulate sensitivity of cells to chemotherapy (Blower et al., 2008).”
MicroRNA-21 targets Sprouty2 and promotes cellular outgrowths
Sayed, D., Rane, S., Lypowy, J., He, M., Chen, I.-Y., Vashistha, H., Yan, L., Malhotra, A., Vatner, D., & Abdellatif, M. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-02-0159 · Cited by 355 · cited 2×
“MiR-21 targetsSPRY2 in cardiomyocytes and SW480 colon cancer cells, enhancing cell migration (Sayed et al., 2008).”
Classification of Proliferative Pulmonary Lesions of the Mouse
Nikitin, A. Y., Alcaraz, A., Anver, M. R., Bronson, R. T., Cardiff, R. D., Dixon, D., Fraire, A. E., Gabrielson, E. W., Gunning, W. T., Haines, D. C., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3376 · Cited by 334 · cited 2×
“All tumors from the survival cohort were analyzed on H&E sections and categorized as hyperplasia, atypical adenomatous hyperplasia, adenoma, adenoma with typia, and adenocarcinoma, according to the Mouse Models of Human Cancer Consortium recommendations (Nikitin et al., 2004).”
Altered miRNA expression in sputum for diagnosis of non-small cell lung cancer
Xie, Y., Todd, N. W., Liu, Z., Zhan, M., Fang, H., Peng, H., Alattar, M., Deepak, J., Stass, S. A., & Jiang, F. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2009.04.004 · Cited by 316 · cited 2×
“The level of miR-21 expression in sputum distinguishes patients with NSCLC from cancer-free control subjects with a greater sensitivity than conventional cytology (Xie et al., 2010).”
microRNA-21 negatively regulates Cdc25A and cell cycle progression in colon cancer cells
Wang, P., Zou, F., Zhang, X., Li, H., Dulak, A., Tomko, R. J., Lazo, J. S., Wang, Z., Zhang, L., & Yu, J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1996 · Cited by 308 · cited 2×
“Targeted deletion of miR-21 in RKO and DLD1 colon cancer cells revealed that miR-21 contributes to tumorigenesis through compromising cell cycle progression and DNA damage-induced checkpoint function through the CDC25A target gene (Wang et al., 2009).”
MicroRNA expression profiles in head and neck cancer cell lines
Tran, N., McLean, T., Zhang, X., Zhao, C. J., Thomson, J. M., O’Brien, C., & Rose, B. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.201 · Cited by 275 · cited 2×
“…samples and cancer cell lines showed increased miR-21 expression in glioblastoma (Chan et al., 2005; Ciafre et al., 2005), head and neck carcinomas (Tran et al., 2007), ovarian cancer (Iorio et al., 2007), B cell lymphoma (Lawrie et al., 2007), hepatocellular (Meng et al., 2007), and…”
Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis
Chen, Y., Knösel, T., Kristiansen, G., Pietas, A., Garber, M. E., Matsuhashi, S., Ozaki, I., & Petersen, I. (2003) · The Journal of Pathology · doi:10.1002/path.1378 · Cited by 265 · cited 2×
“Cancer Cell 18, 282–293, Se Loss of PDCD4 expression in human lung cancer correlates with higher grade and disease stage (Chen et al., 2003).”
Zhang, H., Ozaki, I., Mizuta, T., Hamajima, H., Yasutake, T., Eguchi, Y., Ideguchi, H., Yamamoto, K., & Matsuhashi, S. (2006) · Oncogene · doi:10.1038/sj.onc.1209634 · Cited by 247 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
An autoregulatory loop mediated by miR-21 and PDCD4 controls the AP-1 activity in RAS transformation
Talotta, F., Cimmino, A., Matarazzo, M. R., Casalino, L., De Vita, G., D'Esposito, M., Di Lauro, R., & Verde, P. (2009) · Oncogene · doi:10.1038/onc.2008.370 · Cited by 242 · cited 4×
“miR-21 expression was induced by AP-1 in response to Ras activation, and miR-21 mediated Ras-dependent downregulation of Pdcd4 (Talotta et al., 2009), a known negative regulator of AP-1 transactivation (Goke et al.”
InfluentialMicroRNA expression signature of human sarcomas
Subramanian, S., Lui, W., Lee, C.-H., Espinosa, Í., Nielsen, T. O., Heinrich, M. C., Corless, C. L., Fire, A. Z., & van de Rijn, M. (2007) · Oncogene · doi:10.1038/sj.onc.1210836 · Cited by 229 · cited 2×
“miRNA expression patterns are remarkably reliable markers of cancers; in some cases, they have even proven more reliable than conventional histology (Subramanian et al., 2008).”
Epidermal Expression of the Translation Inhibitor Programmed Cell Death 4 Suppresses Tumorigenesis
Jansen, A. P., Camalier, C. E., & Colburn, N. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2119 · Cited by 212 · cited 2×
“, 2009), a known negative regulator of AP-1 transactivation (Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang et al., 2001).”
Soon, Y. Y., Stockler, M. R., Askie, L. M., & Boyer, M. J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.19.4522 · Cited by 197 · cited 2×
“Despite novel therapies and advances in early detection, NSCLC is often diagnosed at an advanced stage and has a poor prognosis, with a median survival of 8 to 11 months and a 5 year survival rate in patients with NSCLC of only 13% using conventional cytotoxic chemotherapy (Soon et al., 2009).”
Lung cancer in young patients: analysis of a Surveillance, Epidemiology, and End Results database.
Ramalingam, S., Pawlish, K. S., Gadgeel, S. M., Demers, R. Y., & Kalemkerian, G. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.651 · Cited by 196 · cited 2×
“Lung cancer is also the leading cause of cancer-related deaths in the world, with NSCLC accounting for 80%of all cases (Ramalingam et al., 1998).”
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion
Huang, T.-H., Wu, F., Loeb, G. B., Hsu, R., Heidersbach, A., Brincat, A., Horiuchi, D., Lebbink, R. J., Mo, Y.-Y., Goga, A., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.006676 · Cited by 191 · cited 2×
“In addition, epidermal growth factor receptor (EGFR) and HER2/neu signaling positively regulates miR-21 expression in human lung and breast carcinoma cell lines, respectively (Huang et al., 2009; Seike et al., 2009).”
Regulation of the cell cycle gene, BTG2, by miR-21 in human laryngeal carcinoma
Liu, M., Wu, H., Liu, T., Li, Y., Wang, F., Wan, H., Li, X., & Tang, H. (2009) · Cell Research · doi:10.1038/cr.2009.72 · Cited by 189 · cited 2×
“In laryngeal carcinoma, miR-21 targets BTG2 (Liu et al., 2009), a p53 target gene, recently shown to suppress oncogenic Ras activity by reducing the GTP-bound, active state (Buganim et al.”
Yang, H.-S., Jansen, A. P., Nair, R., Shibahara, K., Verma, A. K., Cmarik, J. L., & Colburn, N. H. (2001) · Oncogene · doi:10.1038/sj.onc.1204137 · Cited by 185 · cited 2×
“, 2009), a known negative regulator of AP-1 transactivation (Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang et al., 2001).”
Afonja, O., Juste, D., Das, S., Matsuhashi, S., & Samuels, H. H. (2004) · Oncogene · doi:10.1038/sj.onc.1207983 · Cited by 154 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1
Göke, R., Barth, P. J., Schmidt, A., Samans, B., & Lankat–Buttgereit, B. (2004) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00025.2004 · Cited by 137 · cited 2×
“, 2009), a known negative regulator of AP-1 transactivation (Goke et al., 2004; Jansen et al., 2005; Yang et al., 2003; Yang et al., 2001).”
Sprouty-2 regulates oncogenic K-ras in lung development and tumorigenesis
Shaw, A. T., Meissner, A., Dowdle, J. A., Crowley, D., Magendantz, M., Ouyang, C., Parisi, T., Rajagopal, J., Blank, L. J., Bronson, R. T., et al. (2007) · Genes & Development · doi:10.1101/gad.1526207 · Cited by 131 · cited 4×
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004;Minowada andMiller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
InfluentialSutterlüty, H., Mayer, C., Setinek, U., Attems, J., Ovtcharov, S., Mikula, M., Mikulits, W., Micksche, M., & Berger, W. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0273 · Cited by 115 · cited 2×
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004;Minowada andMiller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
Sprouty and cancer: The first terms report
Lo, T. L., Fong, C. W., Yusoff, P., McKie, A. B., Chua, M., Leung, H. Y., & Guy, G. R. (2006) · Cancer Letters · doi:10.1016/j.canlet.2005.12.032 · Cited by 89 · cited 13×
“We hypothesize that increased miR-21 expression potentiates Ras signaling through inhibition of antagonists of the Ras pathway, such as Spry1, Spry2, Btg2, and Pdcd4 (Casci et al., 1999; Hanafusa et al., 2002; Lo et al., 2006).”
InfluentialBuganim, Y., Solomon, H., Rais, Y., Kistner, D., Nachmany, I., Brait, M., Madar, S., Goldstein, I., Kalo, E., Adam, N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2661 · Cited by 77
RhoB induces apoptosis via direct interaction with TNFAIP1 in HeLa cells
Kim, D., Chung, K., Choi, S., Jung, Y., Park, S., Han, G., Ha, J., Song, K., Choi, N., Kim, H., et al. (2009) · International Journal of Cancer · doi:10.1002/ijc.24617 · Cited by 76 · cited 2×
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009), andRhoB expression is downregulated in human NSCLC, suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
siRNA-mediated knockdown of Pdcd4 expression causes upregulation of p21(Waf1/Cip1) expression
Bitomsky, N., Wethkamp, N., Marikkannu, R., & Klempnauer, K.-H. (2008) · Oncogene · doi:10.1038/onc.2008.115 · Cited by 75 · cited 2×
“PDCD4 is a proapoptotic tumor suppressor gene and has been verified as a miR-21 target in human colorectal and breast cancer cell lines (Afonja et al., 2004; Asangani et al., 2008; Bitomsky et al., 2008; Frankel et al., 2008; Lu et al., 2008; Zhang et al., 2006).”
Classifying microRNAs in cancer: The good, the bad and the ugly
Voorhoeve, P. M., & Agami, R. (2006) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.11.003 · Cited by 63 · cited 2×
“MicroRNAs are evolutionarily conserved, endogenous, nonprotein-coding, 20–23 nucleotide single-stranded RNAs that negatively regulate gene expression in a sequence-specific manner (Cho, 2007; Esquela-Kerscher and Slack, 2006; Voorhoeve and Agami, 2007).”
Sato, N., Fukui, T., Taniguchi, T., Yokoyama, T., Kondo, M., Nagasaka, T., Goto, Y., Gao, W., Ueda, Y., Yokoi, K., et al. (2007) · International Journal of Cancer · doi:10.1002/ijc.22328 · Cited by 56 · cited 1×
“RhoB promotes growth inhibition and induces apoptosis in cancer cells (Kim et al., 2009), andRhoB expression is downregulated in human NSCLC, suggesting a role as a tumor suppressor gene (Sato et al., 2007).”
Fukuda, T., Mishina, Y. M., Walker, M. P., & DiAugustine, R. P. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.12.5270-5281.2005 · Cited by 47 · cited 2×
“We designed a strategy to condition- ally overexpress miR-21 using the Cre-lox system and the CAG- Z-EGFP vector (see Figure S1A and Supplemental Experimental Procedures available online) (Fukuda et al., 2005).”
Hwang, S.-K., Jin, H., Kwon, J. T., Chang, S.-H., Kim, T. H., Cho, C.-S., Lee, K. H., Young, M. R., Colburn, N. H., Beck, G. R., et al. (2007) · Gene Therapy · doi:10.1038/sj.gt.3302983 · Cited by 44 · cited 2×
“Pdcd4 functions both as an inducer of apoptosis and a suppressor of AP-1 activity (Hwang et al., 2007).”
Overexpression of Sprouty 2 in Mouse Lung Epithelium Inhibits Urethane-Induced Tumorigenesis
Minowada, G., & Miller, Y. E. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0147oc · Cited by 22
Defective expression of FasL and Bax in human lung cancer
Badillo-Almaraz, I., Badillo-Salas, C., Villalobos, R., Avalos-D�az, E., & Herrera-Esparza, R. (2003) · Clinical and Experimental Medicine · doi:10.1007/s10238-003-0012-1 · Cited by 4 · cited 2×
“Faslg mRNA is expressed in human lung tumors; however, the Faslg protein is only detected in a small fraction of lung tumors (Badillo-Almaraz et al., 2003). miR-21- mediated translational inhibition could partially explain this find- ing.”
Sprouty 2 gene in mouse lung tumorigenesis
Minowada, G., & Miller, Y. E. (2004) · Chest · doi:10.1378/chest.125.5_suppl.111s · Cited by 4 · cited 2×
“SPRY2, in turn, negatively regulates Ras/MEK/ERK signaling and is a tumor suppressor in NSCLC in both mice (Minowada and Miller, 2004;Minowada andMiller, 2009; Shaw et al., 2007) and humans (Sutterluty et al., 2007).”
Flagged first, then by citations
4 of the 74 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
MicroRNA therapeutics: towards a new era for the management of cancer and other diseases
Rupaimoole, R., & Slack, F. J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.246 · Cited by 4,741
The role of MicroRNAs in human cancer
Peng, Y., & Croce, C. M. (2016) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2015.4 · Cited by 2,566
The role of non-coding RNAs in oncology
Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619
Leva, G. D., Garofalo, M., & Croce, C. M. (2013) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-012513-104715 · Cited by 1,705
“Genetic deletion of miR-21 reduced lung tumor burden following activation of a mutant KrasG12D allele, and correspondingly, a miR-21 transgene increased tumor outgrowth (78).”
BackgroundMicroRNAs in Stress Signaling and Human Disease
Mendell, J. T., & Olson, E. N. (2012) · Cell · doi:10.1016/j.cell.2012.02.005 · Cited by 1,673
“Other miRNAs that appear to participate in similar positive feedback pathways to stably enforce oncogenic signaling programs include miR-21, which is activated by MAPK/ERK signaling and represses negative regulators of this signaling cascade (Hatley et al., 2010), and the miR-143/145 cluster, which is repressed when i…”
BackgroundSelf-citation
Metadata
- Authors
- Hatley, M. E., Patrick, D. M., Garcia, M. R., Richardson, J. A., Bassel-Duby, R., van Rooij, E., & Olson, E. N.
- Affiliations
- The University of Texas Southwestern Medical Center (US)
- Corresponding author
- Olson, Eric N.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2010-09
- Volume
- 18
- Issue
- 3
- Pages
- 282-293
- ISSN
- 1535-6108 (ISSN-L)
- PMC
- PMC2971666
- OpenAlex
- W2169354377
- Semantic Scholar
- ea1aaa83b1883a1290ce31db3401b12568b668c7
- Cited by
- 626
- References
- 74
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 22 · 2022: 38 · 2021: 31 · 2020: 28 · 2019: 29 · 2018: 42 · 2017: 31 · 2016: 40 · 2015: 72 · 2014: 57 · 2013: 62 · 2012: 63
- FWCI
- 16.52
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Cancer Cell (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (submittedVersion)
- PubMed Central (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (R01HL093039)
- National Cancer Institute
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (K12HD000850)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer-related molecular mechanisms research
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Keywords
- miR-21, KRAS, lung carcinogenesis, non-small cell lung cancer, Ras/MEK/ERK pathway, apoptosis inhibition, transgenic mouse model, tumor suppressor microRNA
- MeSH terms
- Animals, Carcinoma, Non-Small-Cell Lung, Cell Transformation, Neoplastic, Humans, Lung Neoplasms, Mice, Nude, Mice, Transgenic, Genes, ras, Signal Transduction, MicroRNAs, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review